Ridgetech (RDGT)
NASDAQ:RDGT
Top Page
Ridgetech
(NASDAQ:RDGT)
Select Model
Select Model
Rating:41Neutral
Price Target:
$3.00
▲(12.78% Upside)
Action:ReiteratedDate:04/09/26
The score is held down primarily by weak financial performance (revenue decline and ongoing operating losses) and bearish technical signals (negative MACD and low RSI). Offsetting factors are limited but include 2025 improvements in net income, cash flow turning positive, and reduced debt; valuation provides little support due to a negative P/E and no indicated dividend yield.
Positive Factors
Improved cash generation
A swing to positive operating and free cash flow in 2025 materially improves the company's ability to fund operations and reduce reliance on external financing. If sustained, positive cash generation supports reinvestment, working capital normalization and gradual deleveraging after multi-year deficits.
Negative Factors
Volatile and declining revenue
An ~18% revenue decline in 2025 and prior volatility make forecasting cash flow and operating leverage difficult. For a distributor with thin margins, persistent top-line weakness undermines scale economics, constrains margin recovery and complicates capital allocation over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved cash generation
A swing to positive operating and free cash flow in 2025 materially improves the company's ability to fund operations and reduce reliance on external financing. If sustained, positive cash generation supports reinvestment, working capital normalization and gradual deleveraging after multi-year deficits.
Read all positive factors
Ridgetech (RDGT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.27M
Dividend YieldN/A
Average Volume (3M)35.98K
Price to Earnings (P/E)―
Beta (1Y)-0.17
Revenue Growth-22.37%
EPS Growth63.14%
CountryUS
Employees939
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)N/A
Shares Outstanding898,906
10 Day Avg. Volume73,880
30 Day Avg. Volume35,985
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.05
P/FCF Ratio9.20
Enterprise Value/Market Cap-4.09
Enterprise Value/Revenue-0.08
Enterprise Value/Gross Profit1.12
Enterprise Value/Ebitda-1.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ridgetech Business Overview & Revenue Model
Company Description
Ridgetech Inc operates as a holding company. The Company, through its subsidiaries, wholesales, distributes, and retails pharmaceutical and other healthcare products....
Ridgetech Financial Statement Overview
Summary
Income Statement
41
Neutral
Balance Sheet
38
Negative
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 111.62M | 119.97M | 154.54M | 148.81M | 164.39M | 133.13M |
| Gross Profit | -8.29M | 3.84M | 31.11M | 34.28M | 36.52M | 29.24M |
| EBITDA | 6.66M | 4.98M | 1.23M | -19.96M | -579.93K | -6.14M |
| Net Income | 12.41M | 10.19M | -4.23M | -21.14M | -3.19M | -8.12M |
Balance Sheet | ||||||
| Total Assets | 61.39M | 64.48M | 95.06M | 90.97M | 106.38M | 106.31M |
| Cash, Cash Equivalents and Short-Term Investments | 13.94M | 12.78M | 20.15M | 18.81M | 18.46M | 22.14M |
| Total Debt | 4.66M | 10.39M | 43.22M | 42.16M | 48.67M | 46.78M |
| Total Liabilities | 31.61M | 34.85M | 80.76M | 74.30M | 83.65M | 81.91M |
| Stockholders Equity | 29.78M | 29.64M | 15.64M | 18.01M | 24.09M | 25.74M |
Cash Flow | ||||||
| Free Cash Flow | 5.35M | 632.50K | -4.08M | -3.60M | -5.69M | -666.47K |
| Operating Cash Flow | 5.35M | 1.25M | -3.16M | -3.28M | -5.39M | -62.29K |
| Investing Cash Flow | 0.00 | -18.14M | -2.04M | -316.10K | -306.14K | -2.00M |
| Financing Cash Flow | -5.87M | 1.51M | 8.00M | 2.37M | 4.84M | 3.08M |
Ridgetech Technical Analysis
Negative
2.66
Price Trends
202.06
Negative
354.95
Negative
285.61
Negative
Market Momentum
-75.48
Positive
32.70
Neutral
2.57
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDGT, the sentiment is Negative. The current price of 2.66 is below the 20-day moving average (MA) of 133.08, below the 50-day MA of 202.06, and below the 200-day MA of 285.61, indicating a bearish trend. The MACD of -75.48 indicates Positive momentum. The RSI at 32.70 is Neutral, neither overbought nor oversold. The STOCH value of 2.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RDGT.
Ridgetech Risk Analysis
Ridgetech disclosed 58 risk factors in its most recent earnings report. Ridgetech reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
HJ Group is subject to restrictions on making payments to us. Q1, 2023
Ridgetech Peers Comparison
UnderperformOutperform
Sector (51)
RDGT
Ridgetech
2.52
-150.48
-98.35%
GEG
Great Elm Group
2.00
0.10
5.26%
SNYR
Synergy CHC
0.58
-1.21
-67.70%
WGRX
Wellgistics Health Inc
0.12
-2.77
-95.85%
Ridgetech Corporate Events
Ridgetech Announces 1-for-150 Reverse Share Split to Take Effect April 7, 2026
Apr 3, 2026
Ridgetech, Inc., a wholesale distributor of pharmaceutical and healthcare products in China listed on Nasdaq under the ticker RDGT, announced on April 3, 2026 that it will execute a 1-for-150 reverse share split of its ordinary shares. The move wi...
Ridgetech Posts Flat Half-Year Revenue but Slightly Stronger Balance Sheet
Mar 5, 2026
Ridgetech, Inc. has furnished its unaudited interim financial results for the six months ended Sept. 30, 2025, reporting essentially flat revenue of $62.8 million compared with the same period in 2024 and a slight increase in gross profit to $2.46...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.